Market Place
Sourcing Support
Nacuity: First Patients In Final Cohort Of NPI-002 Cataract Trial
30 Apr 2024 //
GLOBENEWSWIRE
Nacuity Pharma Appoints Dr. Emmett Cunningham, Jr. to Board of Directors
16 Apr 2024 //
GLOBENEWSWIRE
Arctic and Nacuity Announce EMA Approval to Initiate First Trial of AT-001
12 Mar 2024 //
GLOBENEWSWIRE
Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board
14 Feb 2024 //
GLOBENEWSWIRE
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002
11 Jul 2023 //
GLOBENEWSWIRE
Nacuity achieves target enrolment in RP therapy trial
01 Jun 2023 //
CLINICAL TRIALS ARENA
Nacuity Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001
31 May 2023 //
GLOBENEWSWIRE
Nacuity Expands Board of Directors with Appointment of Dr. Russell Kelley
08 Nov 2022 //
GLOBENEWSWIRE
Nacuity Pharmaceuticals Appoints Russell Kelley to its Board of Directors
08 Nov 2022 //
BIOSPACE
Nacuity and Arctic Therapeutics Enter Licensing Agreement to Develop NPI-001
13 Sep 2022 //
GLOBENEWSWIRE
Nacuity Pharma Announces $16.5M Series B Financing
15 Jun 2022 //
GLOBENEWSWIRE
Nacuity Pharmaceuticals Appoints Robert R. Ruffolo, Ph.D., to Board of Directors
24 Aug 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.